Arizona health officials are confronting a sharp rise in infections caused by Candida auris, a drug‑resistant yeast that can lead to serious or life‑threatening illness. The latest figures released by the Centers for Disease Control and Prevention (CDC) indicate that the state has recorded 171 cases year‑to‑date in 2026, up from 133 cases for the same period in 2025. The increase represents almost a 30 percent jump and underscores a growing challenge for hospitals, nursing homes and other care facilities.
Rising Case Numbers
The CDC’s surveillance data shows that Arizona’s surge is part of a broader national trend. As of July 25, 2026, a total of 3,437 Candida auris cases have been reported across the United States. More than half of the nation’s states now have at least one confirmed infection, and 26 states are specifically listed in the CDC report, including Arizona, Colorado, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Michigan, Mississippi, Nevada, New Jersey, New Mexico, North Carolina, North Dakota, Ohio, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin and West Virginia.
Historical data from the CDC illustrate how rapidly the pathogen has spread over the past decade. In 2016, only 48 clinical cases were documented nationwide. By 2024, that number had climbed to 6,304 cases, reflecting a dramatic escalation in both detection and transmission.
What Is Candida auris?
Candida auris is a species of yeast that is notable for its resistance to multiple antifungal medications. The organism thrives in healthcare environments, where it can move quickly from patient to patient via contaminated surfaces, medical equipment or the hands of caregivers. Because it is difficult to eradicate from the built environment, facilities such as hospitals and long‑term care centers face heightened risk of outbreaks.
Not all individuals who carry C. auris develop symptoms. When symptoms do appear, they often begin with fever and chills. In more severe instances, the fungus can invade the bloodstream, leading to systemic infection that may be life‑threatening. The pathogen’s resistance to standard antifungal drugs limits treatment options, forcing clinicians to rely on a narrow set of less effective or more toxic medications.
Prevention Guidelines
The CDC emphasizes that early detection and strict infection‑control practices are essential to curb the spread of Candida auris. Key recommendations include:
- Screening patients—especially those transferred from other facilities or with a history of colonization—to identify asymptomatic carriers.
- Frequent hand hygiene using alcohol‑based hand sanitizer.
- Rigorous cleaning of patient rooms with disinfectants proven effective against the fungus.
- Isolating infected or colonized patients in separate rooms to limit exposure to others.
- Wearing appropriate personal protective equipment, such as gloves and gowns, when providing care.
By implementing these measures, healthcare providers can reduce the likelihood of transmission and protect vulnerable patients from a pathogen that is increasingly difficult to treat.
Arizona’s recent surge serves as a warning that Candida auris remains a formidable public‑health challenge. Continued surveillance, rapid laboratory identification and adherence to CDC‑recommended infection‑control protocols will be critical in preventing further outbreaks across the state and the nation.
Mitchell Landsberg is the senior reporter for News Raise and focuses on Technology. Mitchell regularly writes about social media platforms and how influencers, industry and general people use them to communicate and make money.
